Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | DPP4 | P27487 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.37 |
| ▸ | FAP | Q12884 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12783344 | 1.00 | RIPK1 (0.51) | RIPK1LMNAHPGDGAADPP4 | |
| SCHEMBL19400524 | 1.00 | RIPK1 (0.51) | RIPK1LMNAHPGDGAADPP4 | |
| SCHEMBL20469386 | 0.94 | HPGD (0.53) | RIPK1LMNAHPGDGAASMN1; SMN2 | |
| SCHEMBL21137551 | 0.94 | HPGD (0.53) | RIPK1LMNAHPGDGAASMN1; SMN2 | |
| SCHEMBL5613392 | 0.94 | HPGD (0.53) | RIPK1LMNAHPGDGAASMN1; SMN2 | |
| SCHEMBL20469340 | 0.87 | RIPK1 (0.49) | RIPK1LMNAHPGDGAADPP4 | |
| SCHEMBL20469339 | 0.87 | RIPK1 (0.49) | RIPK1LMNAHPGDGAADPP4 | |
| SCHEMBL15934326 | 0.82 | HPGD (0.42) | RIPK1LMNAHPGDGAADPP4 | |
| SCHEMBL12058714 | 0.82 | HPGD (0.44) | LMNAHPGDGAADPP4CYP2C19 | |
| SCHEMBL21349768 | 0.80 | RIPK1 (0.40) | RIPK1LMNAHPGDGAACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122580-B2 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. (US) | 2006-10-17 | — | — | US | claimed |
| EP-1546089-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TransTech Pharma Inc. (US) | 2005-06-29 | — | — | EP | claimed |
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TRANSTECH PHARMA, LLC | 2004-06-10 | — | — | US | claimed |
| WO-2004014844-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TRANSTECH PHARMA, INC. (US) | 2004-02-19 | — | — | WO | claimed |
| US-20080146546-A1 | Bicyclic and Tricyclic Heteroaromatic Compounds | NEUROGEN CORPORATION | 2008-06-19 | — | — | US | disclosed |
| US-20080146546-A1 | Bicyclic and Tricyclic Heteroaromatic Compounds | NEUROGEN CORPORATION | 2008-06-19 | — | — | US | disclosed |
| US-7326709-B2 | Bicyclic and tricyclic heteroaromatic compounds | NEUROGEN CORPORATION (US) | 2008-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TFPI, F9, TFPI2 | RIPK1 2949/4885LMNA 75/4885HPGD 1337/4885 |
| US-20080146546-A1 | Bicyclic and Tricyclic Heteroaromatic Compounds | GABBR1, GABBR2, GABRA4 | RIPK1 4716/4885LMNA 2470/4885HPGD 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.